Related Experiment Video
Updated: Feb 4, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Real-world use of PCSK9 inhibitors: A single-center experience
Sinan Sarsam1, Abeer Berry1, George Degheim1
1Providence Providence-Park Hospitals, Department of Cardiology, Michigan State University (Southeast Campus), Southfield, MI, USA.
Insights
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors significantly reduced LDL-C by 63% in patients with hyperlipidemia. These findings highlight PCSK9 inhibitors as effective add-on therapy for managing atherosclerotic cardiovascular disease risk.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Hyperlipidemia is a key risk factor for atherosclerotic cardiovascular disease (ASCVD).
- Many patients exhibit statin intolerance or suboptimal response.
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer an alternative for hyperlipidemia management.
Purpose of the Study:
- To evaluate the real-world effectiveness of PCSK9 inhibitors in a cardiology practice.
- To assess the impact of PCSK9 inhibitors on lipid profiles in patients with hyperlipidemia.
Main Methods:
- Retrospective study involving 17 patients with heterozygous familial hypercholesterolemia or ASCVD.
- Patients received maximally tolerated statins with additional PCSK9 inhibitor therapy.
- Lipid profiles were compared at baseline and 4-6 weeks post-treatment initiation.
Main Results:
- PCSK9 inhibitor treatment averaged 10.7 months.
- Low-density lipoprotein cholesterol (LDL-C) decreased by 63% (154 to 57 mg/dL).
- Total cholesterol reduced by 39%, triglycerides by 19.5%, and HDL-C increased by 10.7%.
Conclusions:
- PCSK9 inhibitors demonstrate significant efficacy as add-on therapy to statins.
- An approximate 63% reduction in LDL-C was observed.
- PCSK9 inhibitors are a valuable option for patients with hyperlipidemia and high cardiovascular risk.
Objective:
Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease. Many patients are intolerant to or have limited benefit from statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been approved for treating hyperlipidemia in these patients. We sought to investigate the impact of these medications in a real-world cardiology practice.
Methods:
This was a retrospective study of 17 patients with either heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol (LDL-C) levels above the treatment target despite maximally tolerated statins. Baseline lipid profile was compared with a repeat lipid profile obtained 4 to 6 weeks after initiating treatment with a PCSK9 inhibitor.
Results:
The average duration of PCSK9 inhibitor treatment was 10.7 months. Lipid profile comparison showed that total cholesterol decreased from 243 ± 72 to 148 ± 39 (mg/dL) (39% reduction), triglycerides decreased from 185 ± 86 to 149 ± 62 (mg/dL) (19.5% reduction), high-density lipoprotein cholesterol increased from 56 ± 20 to 62 ± 26 (mg/dL) (10.7% increase), and LDL-C decreased from 154 ± 30 to 57 ± 32 (mg/dL) (63% reduction) from baseline.
Conclusions:
PCSK9 inhibitors as add-on therapy to maximally tolerated statins resulted in an approximately 63% reduction in LDL-C.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Center of Gravity
Center of Gravity
To determine its location, the principle of moments can be utilized by dividing the object into...
Center of Mass
The knowledge of the center of mass can also help us to describe and predict the motion of objects. For example, when a ball is thrown...
What is an Experiment?

